BRIEF—Novo Nordisk invests big in Chartres, France production facilities

Danish diabetes and obesity giant Novo Nordisk today announced the investment of more than 16 billion Danish kroner ($2.3 billion) starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.

The company said the investment will significantly increase the capacity of the manufacturing site, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.

The investment, which includes capacity for GLP-1 products, will increase Novo Nordisk’s ability to meet future demands for innovative medicines.

“This significant investment announced today confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company. By maximizing the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way,” said Lone Charlotte Larsen, corporate vice president of Novo Nordisk Production Chartres.